Use of Statins to Augment Progenitor Cell Function in Preclinical and Clinical Studies of Regenerative Therapy: a Systematic Review

Stem Cell Reviews and Reports

Volumn 12, Issue 3, 2016, Pages 327-339

  Park, Angela ^a   Barrera Ramirez, Juliana ^a   Ranasinghe, Indee ^a   Pilon, Sophie ^a   Sy, Richmond ^a,b   Fergusson, Dean ^a   Allan, David S ^a,b  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Cellular therapy; Endothelial progenitor; HMG co A reductase inhibitor; Mesenchymal stromal cell; Regenerative therapy; Statin; Vascular repair

Indexed keywords

ATORVASTATIN; CD34 ANTIGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ROSUVASTATIN;

APOPTOSIS; CELL FUNCTION; CELL SURVIVAL; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FRACTURE; HEART INFARCTION; HEART INJURY; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; MESENCHYMAL STROMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGENERATIVE MEDICINE; REVIEW; STEM CELL; STEM CELL TRANSPLANTATION; SYSTEMATIC REVIEW; TRAUMATIC BRAIN INJURY; VASCULAR DISEASE; ANIMAL; DRUG EFFECTS; ENDOTHELIUM CELL; REGENERATION;

ANIMALS; ENDOTHELIAL CELLS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MESENCHYMAL STROMAL CELLS; REGENERATION; STEM CELLS;

EID: 84957966243     PISSN: 15508943     EISSN: 15586804     Source Type: Journal    
DOI: 10.1007/s12015-016-9647-7     Document Type: Review

References (67)

1. Martin, I., Baldomero, H., Tyndall, A., Niederwiesser, D., & Gratwohl, A. (2010). A survey on cellular and engineered tissue therapies in Europe in 2008. Tissue Engineering. Part A, 16, 2419–2427.
2. Dominici, M., Le, B. K., Mueller, I., et al. (2006). Minimal criteria for defining multipotent mesenchymal stromalcells. The International Society for cellular therapy position statement. Cytotherapy, 8, 315–317.
3. Hofmann, N. A., Ortner, A., Jacamo, R. O., et al. (2012). Oxygen sensing mesenchymal progenitors promote neo-vasculogenesis in a humanized mouse model in vivo. PLoS ONE, 7, e44468.
4. Critser, P. J., Voytik-Harbin, S. L., & Yoder, M. C. (2011). Isolating and defining cells to engineer human blood vessels. Cell Proliferation, 33(1), 15–21.
5. Palii, C., Vulesevic, B., Fraineau, S., Pranckeviciene, E., Griffith, A. J., Chu, A., Faralli, H., Li, Y., McNeill, B., Sun, J., Perkins, T. J., Dilworth, F. J., Perez-Iratxeta, C., Suuronen, E. J., Allan, D. S., & Brand, M. (2014). Trichostatin A enhances the vascular repair function of injected human endothelial progenitors by increasing the expression of TAL1-dependent genes. Cell Stem Cell, 14, 644–657.
6. Akyurekli, C., Le, Y., Richardson, R., Fergusson, D., Tay, J., & Allan, D.S. (2014). A systematic review of preclinical studies on the therapeutic potential of mesenchymal stromal cell-derived microvesicles. Stem Cell Reviews and Reports.
7. Xu, R., Chen, J., Cong, X., Hu, S., & Chen, X. (2008). Lovastatin protects mesenchymal stem cells against hypoxia- and serum deprivation-induced apoptosis by activation of PI3K/Akt and ERK1/2. Journal of Cellular Biochemistry, 103, 256–269.
8. Lin, C. L., Cheng, H., Tung, C. W., et al. (2008). Simvastatin reverses high glucose-induced apoptosis of mesangial cells via modulation of Wnt Signaling pathway. American Journal of Nephrology, 28, 290–297.
9. Yan, Y. L., Qiu, B., Wang, J., et al. (2015). High-intensity statin therapy in patients with chronic kidney disease: a systematic review and meta-analysis. BMJ Open, 5, e006886.
10. Jeon, C. Y., Pandol, S. J., Wu, B., et al. (2015). The association of statin use after cancer diagnosis with survival in pancreatic cancer patients: a SEER-medicare analysis. PLoS ONE, 10, e0121783.
11. Criner, G. J., Connett, J. E., Aaron, R. K., et al. (2014). Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. The New England Journal of Medicine, 370, 2201–2210.
12. Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & PRISMA Group. (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine, 6, e1000097.
13. Henderson, V. C., Kimmelman, J., Fergusson, D., Grimshaw, J. M., & Hackam, D. G. (2013). Threats to validity in the design and conduct of preclinical efficacy studies: a systematic review of guidelines for in vivo animal experiments. PLoS Medicine, 10, e1001489.
14. Song, L., Yang, Y. J., Dong, Q. T., et al. (2013). Atorvastatin enhance efficacy of mesenchymal stem cells treatment for swine myocardial infarction via activation of nitric oxide synthase. PLoS ONE, 8(5), e65702.
15. Yang, Y. J., Qian, H. Y., Huang, J., et al. (2008). Atorvastatin treatment improves survival and effects of implanted mesenchymal stem cells in post-infarct swine hearts. European Heart Journal, 29(12), 1578–1590.
16. Yang, Y. J., Qian, H. Y., Huang, J., et al. (2009). Combined therapy with simvastatin and bone marrow-derived mesenchymal stem cells increases benefits in infarcted swine hearts. Arteriosclerosis, Thrombosis, and Vascular Biology, 29(12), 2076–2082.
17. Cai, A., Zheng, D., Dong, Y., et al. (2011). Efficacy of Atorvastatin combined with adipose-derived mesenchymal stem cell transplantation on cardiac function in rats with acute myocardial infarction. Acta Biochimica et Biophysica Sinica (Shanghai), 43(11), 857–866.
18. Wang, A., Shen, F., Liang, Y., & Wang, J. (2011). Marrow-derived MSCs and atorvastatin improve cardiac function in rat model of AMI. International Journal of Cardiology, 150(1), 28–32.
19. Xu, H., Yang, Y. J., Qian, H. Y., et al. (2011). Rosuvastatin treatment activates JAK-STAT pathway and increases efficacy of allogeneic mesenchymal stem cell transplantation in infarcted hearts. Circulation Journal, 75(6), 1476–1485.
20. Zhang, Z., Li, S., Cui, M., et al. (2013). Rosuvastatin enhances the therapeutic efficacy of adipose-derived mesenchymal stem cells for myocardial infarction via PI3K/Akt and MEK/ERK pathways. Basic Research in Cardiology, 108(2), 333.
21. Li, Y., Zhang, D., Zhang, Y., He, G., & Zhang, F. (2010). Augmentation of neovascularization in murine hindlimb ischemia by combined therapy with simvastatin and bone marrow-derived mesenchymal stem cells transplantation. Journal of Biomedical Science, 17, 75.
22. Zhang, Y., Zhang, R., Li, Y., et al. (2012). Simvastatin augments the efficacy of therapeutic angiogenesis induced by bone marrow-derived mesenchymal stem cells in a murine model of hindlimb ischemia. Molecular Biology Reports, 39(1), 285–293.
23. Hu, Z., Zhang, F., Yang, Z., et al. (2008). Combination of simvastatin administration and EPC transplantation enhances angiogenesis and protects against apoptosis for hindlimb ischemia. Journal of Biomedical Science, 15(4), 509–517.
24. Zhou, J., Cheng, M., Liao, Y. H., et al. (2013). Rosuvastatin enhances angiogenesis via eNOS-dependent mobilization of endothelial progenitor cells. PLoS ONE, 8(5), e63126.
25. Cui, X., Chopp, M., Zacharek, A., et al. (2009). Chemokine, vascular and therapeutic effects of combination Simvastatin and BMSC treatment of stroke. Neurobiology of Disease, 36(1), 35–41.
26. Pirzad, J. G., Seidi, S., Sadr, S. S., et al. (2012). Therapeutic effects of a combinatorial treatment of simvastatin and bone marrow stromal cells on experimental embolic stroke. Basic and Clinical Pharmacology and Toxicology, 110(6), 487–493.
27. Mahmood, A., Lu, D., Qu, C., Goussev, A., & Chopp, M. (2007). Treatment of traumatic brain injury with a combination therapy of marrow stromal cells and atorvastatin in rats. Neurosurgery, 60(3), 546–553.
28. Mahmood, A., Goussev, A., Lu, D., et al. (2008). Long-lasting benefits after treatment of traumatic brain injury (TBI) in rats with combination therapy of marrow stromal cells (MSCs) and simvastatin. Journal of Neurotrauma, 25(12), 1441–1447.
29. Han, X., Yang, N., Cui, Y., et al. (2012). Simvastatin mobilizes bone marrow stromal cells migrating to injured areas and promotes functional recovery after spinal cord injury in the rat. Neuroscience Letters, 521(2), 136–141.
30. Qi, Y., Zhao, T., Yan, W., et al. (2013). Mesenchymal stem cell sheet transplantation combined with locally released simvastatin enhances bone formation in a rat tibia osteotomy model. Cytotherapy, 15(1), 44–56.
31. Walter, D. H., Rittig, K., Bahlmann, F. H., et al. (2002). Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation, 105(25), 3017–3024.
32. Roux, N., Brakenhielm, E., Freguin-Bouillant, C., et al. (2012). Progenitor cell mobilizing treatments prevent experimental transplant arteriosclerosis. Journal of Surgical Research, 176(2), 657–665.
33. Steinmetz, M., Pelster, B., Lucanus, E., et al. (2013). Atorvastatin-induced increase in progenitor cell levels is rather caused by enhanced receptor activator of NF-kappaB ligand (RANKL) cell proliferation than by bone marrow mobilization. Journal of Molecular and Cellular Cardiology, 57, 32–42.
34. Wu, V. C., Young, G. H., Huang, P. H., et al. (2013). In acute kidney injury, indoxyl sulfate impairs human endothelial progenitor cells: modulation by statin. Angiogenesis, 16(3), 609–624.
35. Matsumura, M., Fukuda, N., Kobayashi, N., et al. (2009). Effects of atorvastatin on angiogenesis in hindlimb ischemia and endothelial progenitor cell formation in rats. Journal of Atherosclerosis and Thrombosis, 16(4), 319–326.
36. Lavi, R., Zhu, X. Y., Chade, A. R., et al. (2010). Simvastatin decreases endothelial progenitor cell apoptosis in the kidney of hypertensive hypercholesterolemic pigs. Arteriosclerosis, Thrombosis, and Vascular Biology, 30(5), 976–983.
37. Jie, L., Lu, W. M., Li, X. X., et al. (2010). Intensive statin therapy: a favorable adjunct to the improvement of small-diameter vascular grafts. Angiology, 61(5), 427–436.
38. Mohler, E. R., Shi, Y., Moore, J., et al. (2009). Diabetes reduces bone marrow and circulating porcine endothelial progenitor cells, an effect ameliorated by atorvastatin and independent of cholesterol. Cytometry. Part A, 75(1), 75–82.
39. Roan, J. N., Fang, S. Y., Chang, S. W., et al. (2012). Rosuvastatin improves vascular function of arteriovenous fistula in a diabetic rat model. Journal of Vascular Surgery, 56(5), 1381.e1–1389.e1.
40. Emanueli, C., Monopoli, A., Kraenkel, N., et al. (2007). Nitropravastatin stimulates reparative neovascularisation and improves recovery from limb Ischaemia in type-1 diabetic mice. British Journal of Pharmacology, 150(7), 873–882.
41. Wang, W., Lang, J. K., Suzuki, G., Canty, J. M., Jr., & Cimato, T. (2011). Statins enhance clonal growth of late outgrowth endothelial progenitors and increase myocardial capillary density in the chronically ischemic heart. PLoS ONE, 6(9), e24868.
42. Landmesser, U., Engberding, N., Bahlmann, F. H., et al. (2004). Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation, 110(14), 1933–1939.
43. Wang, B., Sun, L., Tian, Y., et al. (2012). Effects of atorvastatin in the regulation of circulating EPCs and angiogenesis in traumatic brain injury in rats. Journal of Neurological Sciences, 319(1-2), 117–123.
44. Zhang, W., & Yan, H. (2012). Simvastatin increases circulating endothelial progenitor cells and reduces the formation and progression of diabetic retinopathy in rats. Experimental Eye Research, 105, 1–8.
45. Erbs, S., Beck, E. B., Linke, A., et al. (2011). High-dose rosuvastatin in chronic heart failure promotes vasculogenesis, corrects endothelial function, and improves cardiac remodeling--results from a randomized, double-blind, and placebo-controlled study. International Journal of Cardiology, 146(1), 56–63.
46. Tousoulis, D., Andreou, I., Tsiatas, M., et al. (2011). Effects of rosuvastatin and allopurinol on circulating endothelial progenitor cells in patients with congestive heart failure: the impact of inflammatory process and oxidative stress. Atherosclerosis, 214(1), 151–157.
47. Liu, H. F., Qi, X. W., Ma, L. L., Yao, D. K., & Wang, L. (2013). Atorvastatin improves endothelial progenitor cell function and reduces pulmonary hypertension in patients with chronic pulmonary heart disease. Experimental and Clinical Cardiology, 18(1), e40–e43.
48. Baran, Ç., Durdu, S., Dalva, K., et al. (2012). Effects of preoperative short term use of atorvastatin on endothelial progenitor cells after coronary surgery: a randomized, controlled trial. Stem Cell Reviews, 8(3), 963–971.
49. Yun, K. H., Shin, I. S., Park, E. M., et al. (2008). Effect of additional statin therapy on endothelial function and prognosis in patients with vasospastic angina. Korean Circulation Journal, 38(12), 638–643.
50. Sobrino, T., Blanco, M., Pérez-Mato, M., Rodríguez-Yáñez, M., & Castillo, J. (2012). Increased levels of circulating endothelial progenitor cells in patients with ischaemic stroke treated with statins during acute phase. European Journal of Neurology, 19(12), 1539–1546.
51. Yoshida, O., Kondo, T., Kureishi-Bando, Y., et al. (2010). Pitavastatin, an HMG-CoA reductase inhibitor, ameliorates endothelial function in chronic smokers. Circulation Journal, 74(1), 195–202.
52. Antonio, N., Soares, A., Fernandes, R., et al. (2014). Endothelial progenitor cells in diabetic patients with myocardial infarction – can statins improve their function? European Journal of Pharmacology, 741, 25–36.
53. Yuan, Q., Hu, C. P., Gong, Z. C., et al. (2015). Accelerated onset of senescence of endothelial progenitor cells in patients with type 2 diabetes mellitus: role of dimethylarginine dimethylaminohydrolase 2 and asymmetric dimethylarginine. Biochemical and Biophysical Research Communications, 458, 869–876.
54. Kim, J., Piao, Y., Pak, Y. K., et al. (2015). Umbilical cord mesenchymal stromal cells affected by gestational diabetes mellitus display premature aging and mitochondrial dysfunction. Stem Cells and Development, 24, 575–586.
55. Yu, K. R., & Kang, K. S. (2013). Aging-related genes in mesenchymal stem cells: a mini-review. Gerontology, 59, 557–563.
56. Zeng, H. L., Qin, Y. L., Chen, H. Z., et al. (2014). Effects of nicotine on proliferation and survival in human umbilical cord mesenchymal stem cells. Journal of Biochemical and Molecular Toxicology, 28, 181–189.
57. Klowak, J., Chung, J., & Allan, D.S. (2012). Cord blood banking for regenerative therapy. In D.S. Allan and D. Strunk (Eds.), Regenerative therapy using blood-derived stem cells. Science.
58. Fraineau, S., Palii, C.G., Allan, D.S., & Brand, M. (2014). Epigenetic regulation of endothelial stem/progenitor cell-mediated vascular repair. FEBS Journal.
59. Iafolla, M. A. J., Tay, J., & Allan, D. S. (2014). Transplantation of umbilical cord blood-derived cells for novel indications in regenerative or immunomodulatory therapy: a scoping review of clinical studies. Biology of Blood and Marrow Transplantation, 20, 20–25.
60. Eseonu, O. I., & De Bari, C. (2015). Homing of mesenchymal stem cells: mechanistic or stochastic? Implications for targeted delivery in arthritis. Rheumatology (Oxford), 54, 210–218.
61. (1994). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 344,1383–1389.
62. Shepherd, J., Cobbe, S. M., Ford, I., et al. (1995). Prevention of coronary heart disease with pravastatin in men with hypercholersterolemia: west of Scotland Coronary Prevention Study Group. The New England Journal of Medicine, 333, 1301–1307.
63. Hamadini, M., Gibson, L. F., Remick, S. C., et al. (2013). Sibling donor and recipient immune modulation with atorvastatin for the prophylaxis of acute graft-versus-host-disease. Journal of Clinical Oncology, 31, 4416–4423.
64. Manocha, D., Bansal, N., Gumaste, P., & Brangman, S. (2013). Safety profile of high-dose statin therapy in geriatric patients with stroke. Southern Medical Journal, 106, 658–664.
65. Mohassel, P., & Mammen, A. L. (2013). Statin-associated autoimmune myopathy and anti-HMGCR autoantibodies. Muscle and Nerve, 48, 477–483.
66. Dimmeler, S., Aicher, A., Vasa, M., et al. (2001). HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. Journal of Clinical Investigation, 108, 391–397.
67. Llevadot, J., Murasawa, S., Kureishi, Y., et al. (2001). HMG-coAreductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. Journal of Clinical Investigation, 108, 399–405.